Google Search and YouTube revenues are projected to grow at 10% and 11%, respectively in Q4, showing slower growth compared ...

Is CyberArk overvalued despite recent growth from Venafi acquisition? Find out why it's rated as a Hold in this financial ...

The Finance Ghost explains how the tech conglomerate's resilience, AI strategy, and long-term growth potential make it his ...

Watch this special Budget 2025 coverage only on Business Today TV! BTTV brings you a new market show - 'Daily Calls,' where you can gain invaluable insights and clarity on your market queries ...

Sanofi confirms the expectation of a strong rebound in business EPS with growth at a low double-digit percentage at CER (before share buyback). 6 Sanofi intends to execute a share buyback program ...

6 Applying average January 2025 exchange rates, the currency impacts are estimated between +2% and +3% on sales and +2% and +3% on business EPS. 7 At CER ... in our website are provided solely for ...

Sanofi confirms the expectation of a strong rebound in business EPS with growth at a low double ... on our websites and newsletters. How we use your information depends on the product and service ...

Pharma launches up 56.5%, reaching sales of €0.8 billion, 8% of total sales, led by ALTUVIIIO Dupixent sales up 16.0% to €3.5 billion Vaccines sales up 10.8% to €2.2 billion, driven by Beyfortus sales ...

Q4: sales growth of 10.3% at CER 1 and business EPS 2 of €1.31 Pharma launches up 56.5%, reaching sales of €0.8 billion, 8% of total sales, led by ALTUVIIIO Dupixent sales up 16.0% to €3.5 ...

Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025Paris, January 30, 2025Q4: ...

Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025 Paris, January 30, 2025 Q4: sales growth of 10.3% at CER 1 and business EPS ...